Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873478 | 0.91 | BACE1 (0.77) | BACE1CTSD | |
| SCHEMBL2875771 | 0.90 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL2876604 | 0.90 | BACE1 (0.78) | BACE1CTSD | |
| SCHEMBL2877633 | 0.90 | BACE1 (0.74) | BACE1CTSD | |
| SCHEMBL2877299 | 0.89 | BACE1 (0.73) | BACE1CTSD | |
| SCHEMBL2875103 | 0.89 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL2871912 | 0.89 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL2875995 | 0.88 | BACE1 (0.74) | BACE1CTSD | |
| SCHEMBL13001312 | 0.88 | BACE1 (0.79) | BACE1CTSD | |
| SCHEMBL12976694 | 0.87 | BACE1 (0.79) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | BACE1 13/4885CTSD 120/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | BACE1 13/4885CTSD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.